DAIC

APRIL 17, 2024

to develop the next generation technology for cardiopulmonary resuscitation, announced today that Mike Black will be advising the Company as its first Chief Strategy Officer. His background in leading the development of innovative resuscitation and EMS medical devices is uniquely strong. CPR Therapeutics, Inc.

Cardiac Arrest 105

Cardiac Arrest Innovation Technology Outcomes 105

DAIC

DECEMBER 11, 2023

Since its inception in 2015, Biomodex has invested over 12 million EUR in IP and R&D, leading to the development of several innovative products and technology advances which will be very synergistic to Mentice’s current portfolio.

Anatomy 105

Anatomy Innovation Technology 105

DAIC

FEBRUARY 28, 2024

Health technology giant Royal Philips has announced its proposal to appoint Charlotte Hanneman as member of the Board of Management to fulfill the role of Chief Financial Officer (CFO), filling the position held by Abhijit Bhattacharya, who will be retiring at the end of September after in that role since 2015.

Technology 52

Technology Innovation 52

GEMMS

APRIL 8, 2024

With the recent changes to MIPS reporting requirements, healthcare providers seek innovative solutions to streamline their reporting processes while maximizing incentives and improving patient care. What is MIPS?

Medicare 52

Medicare Innovation Medicaid Patient Care 52

Vector Remote

APRIL 14, 2023

History & Future of Cardiac Remote Patient Monitoring Healthcare reforms fueled by government legislation and recent technological innovations have propelled cardiac remote patient monitoring to the forefront in the early 2020s, but the history of cardiac remote patient monitoring dates to more than half a century ago.

Pacemaker 52

Pacemaker Technology COVID-19 Arrhythmia 52

GEMMS

MARCH 7, 2024

EHR technology certified to the 2015 Cures Update must be in place by October 3, 2023. This innovative solution can assist clinicians in navigating the complexities of MIPS, enhancing overall efficiency, and ensuring compliance with the latest reporting requirements. For a minimum of 90 days, report all required measures.

Medicare 52

Medicare CMS Document Technology 52

Dr. Malcolm Kendrick

OCTOBER 30, 2024

GlaxoSmithKline: $400K Liposcience: £50K HPS2-THRIVE trial of niacin/laropiprant (2005-2015) Merck: £53M plus drug supply HPS3/TIMI55-REVEAL trial of anacetrapib (2010-2022) Merck: £108M plus drug supply HPS 4/TIMI 65 – ORION-4 (2017-ongoing) Novartis Pharma AG Switzerland: £73.7M SEARCH trial of simvastatin dose (1997-2010) Merck: £22.7M

Cholesterol 145

Cholesterol Article Research Diet 145